步长制药：第三季度归母净利润2.41亿元，同比增加195.44%

Core Viewpoint - The company reported a decline in revenue for Q3 2025 while achieving significant growth in net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved an operating income of 2.805 billion yuan, a year-on-year decrease of 9.02% [1] - The net profit attributable to shareholders for Q3 2025 was 241 million yuan, reflecting a year-on-year increase of 195.44% [1] - Basic earnings per share for Q3 2025 were 0.2282 yuan [1] - For the first three quarters of 2025, the company reported an operating income of 8.469 billion yuan, a slight year-on-year decline of 0.54% [1] - The net profit attributable to shareholders for the first three quarters was 868 million yuan, showing a year-on-year increase of 177.54% [1] - Basic earnings per share for the first three quarters were 0.8208 yuan [1]